IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call & Webcast on ...
June 04 2019 - 7:05AM
Business Wire
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical stage immunotherapy company, announced today that it will
hold a conference call and webcast on Wednesday, June 12, 2019, at
8:00 a.m. ET. This call will provide an update on its ongoing phase
2 clinical trials with Merck’s Keytruda® in diffuse large B-cell
lymphoma (DLBCL).
Financial analysts are invited to join the conference call by
dialing (866) 211-2304 (U.S. and Canada) or (647) 689-6600
(International) using the conference ID: 9685423
Other interested parties will be able to access the live audio
webcast at this link:
https://ir.imv-inc.com/events-and-presentations. The webcast will
be recorded and made available on the IMV website for 30 days
following the call.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com
About DPX-Survivac
DPX-Survivac is the lead candidate in IMV’s new class of
immunotherapies that programs targeted T cells in vivo. It has
demonstrated the potential for industry-leading targeted,
persistent, and durable T cell activation. IMV believes this MOA is
key to generating durable solid tumor regressions. DPX-Survivac
consists of survivin-based peptide antigens formulated in IMV’s
proprietary DPX drug development platform. DPX-Survivac is believed
to work by eliciting a cytotoxic T cell immune response against
cells presenting survivin peptides.
Survivin, recognized by the National Cancer
Institute (NCI) as a promising tumor-associated antigen, is
broadly over-expressed in most cancer types, and plays an essential
role in antagonizing cell death, supporting tumor-associated
angiogenesis, and promoting resistance to anti-cancer
therapies. IMV has identified over 15 cancer indications in
which the over-expression of survivin can be targeted by
DPX-Survivac.
DPX-Survivac has received Fast Track designation from
the U.S. Food and Drug Administration (FDA) as
maintenance therapy in advanced ovarian cancer, as well
as orphan drug designation status from the
U.S. FDA and the European Medicines
Agency (EMA) in the ovarian cancer indication. It is
currently being evaluated in multiple Phase 1b/2 clinical
trials.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form. Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190604005531/en/
INVESTOR RELATIONS:Marc Jasmin, Senior Director,
Investor Relations and CommunicationsO: (902) 492-1819 ext :
1042M: (514) 917-9481 E: mjasmin@imv-inc.comMEDIA:Andrea
Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024